<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0873-2159</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Pneumologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Pneumol]]></abbrev-journal-title>
<issn>0873-2159</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Pneumologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0873-21592010000200002</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Comparison of interferon-&#947; release assay and tuberculin test for screening in healthcare workers]]></article-title>
<article-title xml:lang="pt"><![CDATA[Comparação do teste de libertação do interferão -&#947; e da prova de tuberculina no rastreio de profissionais de saúde]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[José Torres]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Rui]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sá]]></surname>
<given-names><![CDATA[Raul]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[Maria João]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[Carla]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nienhaus]]></surname>
<given-names><![CDATA[Albert]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital São João Allergy and Clinical Immunology Division ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Porto University Faculty of Medicine ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Hospital São João Clinical Pathology Division ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A04">
<institution><![CDATA[,Health and Welfare Services  ]]></institution>
<addr-line><![CDATA[Hamburg ]]></addr-line>
<country>Germany</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2010</year>
</pub-date>
<volume>16</volume>
<numero>2</numero>
<fpage>211</fpage>
<lpage>221</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0873-21592010000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0873-21592010000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0873-21592010000200002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Healthcare workers (HCWs) have an increased risk of tuberculosis (TB). Screening for latent tuberculosis infection and active TB is therefore essential in infection control programs. Tuberculin skin test (TST) and Interferon-ƒÁ Release Assay (IGRA) were used simultaneously in 1686 HCWs between May 2007 and April 2009. A chest X-ray was performed in order to exclude active TB when TST was .10mm or IGRA was positive and in HCWs with TB contact or symptoms. IGRA was positive in 33.1% and TST was >10mm in 78.3% of the HCWs. The proportionof positive IGRA results increased with the TST diameter. In those with a TST >15mm, 49.2% were IGRA positive. TST was more than twice as often positive than the IGRA. Therefore, TST+/IGRA- results were more often observed than concordant negative or positive results. In none of the HCWs with a TST+/IGRA- result active TB was diagnosed during the study period. Repeated BCG vaccination increased the number of TST+/IGRA- discordance. The smaller the interval after BCG vaccination, the higher was the TST+/IGRA- discordance. In the screened HCWs population, active TB was diagnosed in 9. At the time of diagnosis TST and IGRA were positive in all active TB cases. The study period covers 24 months, therefore the average annual incidence rate was 268/100 000. TB burden in HCWs in Portugal is high. Considering the limitations that TST and IGRA present, the best solution seems to be the use of both, using the IGRA higher specificity for confirming a positive TST, taking advantage of the best characteristics of each test.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Os profissionais de saúde (PS) têm um risco aumentado de tuberculose. O rastreio da tuberculose latente e da tuberculose activa é portanto essencial nos programas de controlo de infecção. Entre Maio de 2007 e Abril de 2009, foram utilizados simultaneamente a prova de tuberculina (PT) e o teste de libertação do interferão-ã (IGRA) em 1686 PS. Quando PT &#8805;10mm ou IGRA positivo, e em PS com contacto com tuberculose ou sintomáticos, foi realizada uma radiografia torácica para excluir tuberculose activa. O IGRA foi positivo em 33,1% e a PT foi >10mm em 78.3% dos PS. A proporção de resultados IGRA positivos aumentou com o diâmetro da PT. Nos PS com PT >15mm, 49.2% são IGRA positivos. A PT foi positiva em mais do dobro dos casos do IGRA. Assim, foram observados mais frequentemente resultados PT+/IGRA- do que resultados concordantes negativos ou positivos. Em nenhum PS com resultado PT+/IGRA- foi diagnosticada tuberculose activa durante o período do estudo. A vacinação repetida pelo BCG aumentou o número de casos discordantes PT+/IGRA -. Quanto menor o intervalo após a vacinação pelo BCG, maior a discordância PT+/IGRA -. Na população de PS rastreada, foram diagnosticados 9 casos de tuberculose activa, sendo todos PT e IGRA positivos na altura do diagnóstico. Este estudo durou 24 meses, pelo que a taxa de incidência anual média foi de 268/100 000. A tuberculose é um problema importante nos PS em Portugal. Considerando as limitações que a PT e IGRA apresentam, a melhor solução parece ser o uso de ambos, utilizando a maior especificidade do IGRA para confirmar uma PT positiva, aproveitando as melhores características de cada teste.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[healthcare workers]]></kwd>
<kwd lng="en"><![CDATA[tuberculin skin test]]></kwd>
<kwd lng="en"><![CDATA[interferon- release assay]]></kwd>
<kwd lng="en"><![CDATA[Portugal]]></kwd>
<kwd lng="pt"><![CDATA[Tuberculose]]></kwd>
<kwd lng="pt"><![CDATA[profissionais de saúde]]></kwd>
<kwd lng="pt"><![CDATA[prova de tuberculina]]></kwd>
<kwd lng="pt"><![CDATA[teste de libertação do interferão-]]></kwd>
<kwd lng="pt"><![CDATA[Portugal]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p><b>Comparison of interferon-&#947; release assay and tuberculin test for screening    in healthcare workers</b></p>      <p>&nbsp;</p>      <p><b>José Torres Costa</b> <b><sup>1,2,3</sup></b>, <b>Rui Silva</b> <b><sup>1,2,3</sup></b>, <b>Raul Sá</b>  <b><sup>1</sup></b>, <b>Maria João Cardoso</b> <b><sup>4</sup></b>, <b>Carla Ribeiro</b> <b><sup>1</sup></b>,  <b>Albert Nienhaus</b> <b><sup>5</sup></b></p>      <p>&nbsp;</p>      <p><sup>1</sup> Occupational Health Division</p>      <p><sup>2</sup> Allergy and Clinical Immunology Division, Hospital São João, Alameda Professor Hernâni Monteiro, Porto–Portugal</p>      <p><sup>3</sup> Faculty of Medicine, Porto University, Alameda Professor Hernâni Monteiro, Porto-Portugal</p>      <p><sup>4</sup> Hospital São João, Clinical Pathology Division, Alameda Professor Hernâni Monteiro, Porto–Portugal</p>      <p><sup>5</sup> Accidents Insurance and Prevention in the Health and Welfare Services, Hamburg, Germany</p>      <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><b><a name="topc1"></a><a href="#c1">Correspondência</a></b></p>      <p>&nbsp;</p>      <p><b>Abstract</b></p>      <p>Healthcare workers (HCWs) have an increased risk of tuberculosis (TB). Screening for latent tuberculosis infection and active TB is therefore essential in infection control programs. Tuberculin skin test (TST) and Interferon-ƒÁ Release Assay (IGRA) were used simultaneously in 1686 HCWs between May 2007 and April 2009. A chest X-ray was performed in order to exclude active TB when TST was .10mm or IGRA was positive and in HCWs with TB contact or symptoms. IGRA was positive in 33.1% and TST was >10mm in 78.3% of the HCWs. The proportionof positive IGRA results increased with the TST diameter. In those with a TST >15mm, 49.2% were IGRA positive. TST was more than twice as often positive than the IGRA. Therefore, TST+/IGRA- results were more often observed than concordant negative or positive results. In none of the HCWs with a TST+/IGRA- result active TB was diagnosed during the study period. Repeated BCG vaccination increased the number of TST+/IGRA- discordance.</p>     <p>The smaller the interval after BCG vaccination, the higher was the TST+/IGRA- discordance.</p>     <p>In the screened HCWs population, active TB was diagnosed in 9. At the time of diagnosis TST and IGRA were positive in all active TB cases. The study period covers 24 months, therefore the average annual incidence rate was 268/100 000.</p>     <p>TB burden in HCWs in Portugal is high. Considering the limitations that TST and IGRA present, the best solution seems to be the use of both, using the IGRA higher specificity for confirming a positive TST, taking advantage of the best characteristics of each test.</p>     <p><b>Key-words:</b> Tuberculosis, healthcare workers, tuberculin skin test, interferon-<b>&#947;</b>    release assay, Portugal.</p>      <p>&nbsp;</p>      <p><b>Comparação do teste de libertação do interferão –&#947; e da prova de tuberculina no rastreio de profissionais de saúde</b></p>      ]]></body>
<body><![CDATA[<p><b>Resumo</b></p>      <p>Os profissionais de saúde (PS) têm um risco aumentado de tuberculose. O rastreio da tuberculose latente e da tuberculose activa é portanto essencial nos programas de controlo de infecção. Entre Maio de 2007 e Abril de 2009, foram utilizados simultaneamente a prova de tuberculina (PT) e o teste de libertação do interferão-ã (IGRA) em 1686 PS. Quando PT &#8805;10mm ou IGRA positivo, e em PS com contacto com tuberculose ou sintomáticos, foi realizada uma radiografia torácica para excluir tuberculose activa. O IGRA foi positivo em 33,1% e a PT foi &gt;10mm em 78.3% dos PS. A proporção de resultados IGRA positivos aumentou com o diâmetro da PT. Nos PS com PT &gt;15mm, 49.2% são IGRA positivos. A PT foi positiva em mais do dobro dos casos do IGRA. Assim, foram observados mais frequentemente resultados PT+/IGRA- do que resultados concordantes negativos ou positivos. Em nenhum PS com resultado PT+/IGRA- foi diagnosticada tuberculose activa durante o período do estudo. A vacinação repetida pelo BCG aumentou o número de casos discordantes PT+/IGRA -. Quanto menor o intervalo após a vacinação pelo BCG, maior a discordância PT+/IGRA -.</p>     <p>Na população de PS rastreada, foram diagnosticados 9 casos de tuberculose activa, sendo todos PT e IGRA positivos na altura do diagnóstico. Este estudo durou 24 meses, pelo que a taxa de incidência anual média foi de 268/100 000.</p>      <p>A tuberculose é um problema importante nos PS em Portugal. Considerando as limitações que a PT e IGRA apresentam, a melhor solução parece ser o uso de ambos, utilizando a maior especificidade do IGRA para confirmar uma PT positiva, aproveitando as melhores características de cada teste.</p>      <p><b>Palavras-chave: </b>Tuberculose, profissionais de saúde, prova de tuberculina,    teste de libertação do interferão-<b>&#947;</b>, Portugal.</p>      <p>&nbsp;</p>      <p><b>Introduction</b></p>      <p>The increased risk of healthcare workers (HCWs) for tuberculosis is well established<sup><a href="#1">1-3</a></sup><a name="top1"></a>.</p>     <p>Screening    HCWs for latent tuberculosis infection (LTBI) and active tuberculosis (TB) is    therefore fundamental in infection control programs in hospitals<sup><a href="#4">4</a></sup><a name="top4"></a>.    For about a century, the tuberculin skin test (TST) has been used to detect    LTBI. The TST measures the hypersensitive response to purified protein derivative    (PPD), a crude mixture of antigens,many of which are shared by <i>M. tuberculosis,    M. bovis </i>(source of the Calmette -Guérin bacillus;BCG), and several non–tubercular    mycobacteria (NTM). Although the TST has proved to be useful in clinical practice,    it has known limitations, including crossreactivity with BCG and NTM infections<sup><a href="#5">5</a></sup><a name="top5"></a>.</p>        <p>Advances in molecular biology have led to the development of a new <i>in vitro    </i>assay that measures interferon (INF)-ã released by sensitized T cells after    stimulation with <i>M. tuberculosis </i>antigens. These antigens include early    secreted antigenic target (ESAT) -6 and culture filtrate protein (CFP) -10.    ESAT -6 and CFP -10 are encoded by genes located within the region of difference    (RD) -1 segment of the <i>M. tuberculosis </i>genome. Two new T-cell-based    tests for diagnosing LTBI have been developed and licensed for commercial distribution:    QuantiFERON (QTF)- TB Gold in Tube® (Cellestis, Victoria, Australia) uses an    enzyme-linked immunosorbent assay (ELISA) to measure antigen–specific production    of INF -ã by circulating T cells in whole blood; T -SPOT.TB® (Oxford Immunotec,    Oxford, United Kingdom) uses the Elispot technique to measure peripheral blood    mononuclear cells that produce INF -ã. These tests are more specific than the    TST using PPD, because they use antigens not shared by any of the BCG vaccine    strains nor by the more common species of NTM (e.g. <i>M. avium</i>)<sup><a href="#6">6</a></sup><a name="top6"></a>.    Research on test performance has shown that assays using RD1 antigens are more    specific than TST, have a better correlation with surrogate measures of exposure    to <i>M. tuberculosis </i>in low incidence settings, and exhibit less cross-reactivity    due to BCG vaccination than the TST<sup><a href="#7">7</a><a name="top7"></a>,<a href="#8">8</a><a name="top8"></a></sup>.    In the absence of a gold standard for LTBI, active TB is used as a surrogate    for LTBI to judge sensitivity. In a meta -analysis, the pooled sensitivity and    specificity for the IGRA were higher than for TST<sup><a href="#9">9</a><a name="top9"></a></sup>.    The IGRA has potential advantages besides its greater specificity, including    logistical convenience (no second patient contact for reading the test), easier    interpretation of the test results (cut-off point is independent from the risk    status of the patient) and the ability to perform serial testing without inducing    the boosting phenomenon. A recent study demonstrated that the IGRA has merits    in screening close contacts for LTBI in low incidence areas<sup><a href="#10">10</a><a name="top10"></a></sup>.    Within the first two years after contact, the progression rate to active TB    for IGRA -positive was three times higher than with TST positive contacts.</p>        ]]></body>
<body><![CDATA[<p>So    far only few systematic investigations of LTBI in HCWs using the IGRA have been    published<sup><a href="#11">11-17</a><a name="top11"></a></sup>. Therefore,    we studied the prevalence of LTBI in Portuguese HCWs and compared the performance    of the IGRA to the TST.</p>       <p>&nbsp;</p>      <p><b>Materials and methods </b></p>      <p><b>Study setting and study subjects</b></p>      <p>In compliance with EU regulations, the Hospital S. João, Porto – Portugal,    implemented an Occupational Health Division for the hospital staff. Since May    2007 the workers of this hospital have been offered TB screening with TST and    IGRA simultaneously by this Division. Screening follows the Centers for Disease    Control and Prevention (CDC) guidelines<sup><a href="#4">4</a><a name="top4"></a></sup>.    Upon commencement of employment, all workers are examined to exclude active    TB and to assess their pre-employment status. Depending on risk assessment,    the examination is repeated annually or every other year. HCWs with close patient    contact in the infection and TB wards are considered at high risk, workers with    regular patient contact in the other wards are considered at medium risk and    workers with no regular patient contact or no contact with biological material    are considered at low risk. Screening is performed annually for those with contact    with TB patients or infectious material. For all other HCWs screening is scheduled    biannually. After unprotected contact with na infectious patient or material,    an additional screening is performed as well.</p>       <p>The data presented here comprise    all HCWs screened between May 2007 and April 2009 using TST and IGRA simultaneously.    TST was only performed when the diameter of a previous TST was below 15 mm or    when no previous TST result was known. A chest X-ray was performed in order    to exclude active pulmonary disease when TST was 10 mm or higher or IGRA was    positive and in HCWs with TB contact or symptoms.</p>        <p>BCG vaccination was assessed    through the individual vaccination register. If no register was available, vaccination    status was verified by scars. According to the Portuguese National Vaccination    Plan<sup><a href="#18">18</a><a name="top18"></a></sup>, BCG vaccination is    administered in newborns, and until January 2000 was repeated if TST diameter    was below 5 mm. Therefore, every HCW was considered to have been vaccinated    at least once.</p>      <p>&nbsp;</p>      <p><b>Tuberculin skin test</b></p>      <p>TST was performed by trained personnel following standard procedures. Briefly, 0.1 mL (2 TU) of purified protein derivate (PPD, RT23; Statens Serum Institute, Copenhagen, Denmark) were injected in the volar side of the forearm of the participants and read 72 to 96 hours afterwards. The transverse diameter of the induration was measured by experienced personnel.</p>      ]]></body>
<body><![CDATA[<p>Before the TST application, the interview was performed and blood for the IGRA was drawn. For the IGRA, the QuantiFERON- -TB® Gold In -Tube Assay (Cellestis Limited, Carnegie, Australia) was used. This whole blood assay uses overlapping peptides corresponding to ESAT -6, CFP -10, and a portion of tuberculosis antigen TB7.7 (Rv2654).</p>      <p>Stimulation of the antigenic mixture occurs within the tube used to collect blood. Tubes were incubated at 37oC overnight before centrifugation, and INF-ã release was measured by ELISA following the protocol of the manufacturer. All assays performed met the manufacturer’s quality control standards.</p>     <p>The test was considered positive when INF -ã was &#8805; 0.35 IU after correction for the negative control. Observers were blinded to the results of the TST results.</p>      <p>&nbsp;</p>      <p><b>Statistical analysis</b></p>      <p>Chi-square test was used to compare frequencies of test results among different    groups of participants. For ordered risks, the proportions of positive test    results were compared using the chi-square test of trend.</p>        <p>The agreement between    TST and QFT independent from the agreement by chance alone was assessed by calculating    Kappa values for TST &gt;10 mm and TST &gt;15 mm. P&lt;0.05 was considered statistically    significant. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were    calculated for different putative predictive variables using conditional logistic    regression. Model building was performed backwards using the chance criteria    for variable selection<sup><a href="#19">19</a><a name="top19"></a></sup>.</p>       <p>Data    analysis was performed with SPSS, Version 14 (SPSS Inc., Chicago, Illinois).</p>        <p>All people gave their informed consent prior to their inclusion in the study.    No additional data were collected for the study purpose only and analysis was    performed with anonymous data. Therefore, no endorsement by an ethics committee    was required.</p>      <p>&nbsp;</p>      ]]></body>
<body><![CDATA[<p><b>Results</b></p>      <p>TST and QFT were performed in 1686 HCWs. The population available for analysis    comprises 1682 HCWs since QFT was undetermined in 4 (0.2%). Their characteristics    are described in Table I. The TST was &gt;10 mm in 78.3% and the QFT was positive    in 33.1%. The proportion of positive QFT results increase with the diameter    of the TST (Table II). In those with a TST &gt;15 mm, 49.2% are positive in    the QFT. Agreement between TST and QFT was higher with &gt;15 mm instead of    &gt;10 mm as cut off for TST (0.18 versus 0.29). For both cut offs agreement    decreased with number of BCG vaccination (Table III), but even in those vaccinated    at birth only, Kappa was low for both the &gt;10 mm (0.26) and for the &gt;15    mm (0.37) cut off for TST. Moving the cut off for TST from &gt;10 to &gt;15    mm did not yield good agreement between QFT and TST (Table III) and as a drawback    increased the number of TST -/QFT+ discordant results from 33 (2%) to 202 (12%)    as can be calculated from Table II. Therefore, further analysis were undertaken    with TST &gt;10 mm as cut off.</p>      <p>&nbsp;</p>     <p><b>Table I</b> - Study population for comparison of IGRA with TST (n=1682)</p> <img src="/img/revistas/pne/v16n2/16n2a02t1.gif">      
<p>&nbsp;</p>     <p><b>Table II</b> - TST diameter by IGRA results</p> <img src="/img/revistas/pne/v16n2/16n2a02t2.gif">      
<p>&nbsp;</p>     <p><b>Table III</b> -Agreement assessed by Kappa between TST and QFT depending on number of BCG vaccinations and cut off for TST</p> <img src="/img/revistas/pne/v16n2/16n2a02t3.gif">      
<p>&nbsp;</p>      <p>With age the proportion of positive TST or QFT    increased (Table IV). In those 60 years or older the proportion of positive    TST declined compared to those 40-40 years or 50-59 years old while for the    QFT a linear association was seen over all age groups. Repeated BCG vaccination    was not associated with the probability of a positive TST but decreased the    proportion of positive QFT. When a BCG vaccination was performed during the    last 10 years, the odds ratio for a positive TST was increased with a borderline    statistically significant confidence interval (OR 1.5; 95%CI 1.0 -2.4) and the    odds ratio for a positive QFT was well below 1 (OR 0.4; 95%Ci 0.3 -0.7).</p>       ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><b>Table IV</b> – Proportion of tuberculin skin test (TST) >10 mm and positive interferon-ã-release  assay (IGRA) and the respective adjusted odds ratios (OR) and 95% confi dence intervals (CI) for different  putative risk factors</p> <img src="/img/revistas/pne/v16n2/16n2a02t4.gif">      
<p>&nbsp;</p>            <p>Profession    was not associated with the TST, while doctors had a slightly increased odds    ratio for a positive QFT (OR 1.4; 95%CI 1.0- 2.0), again with a borderline statistically    significant confidence interval. Risk assessment, according to the CDC guidelines<sup><a href="#4">4</a><a name="top4"></a></sup>,    was neither associated with TST nor with QFT while a positive association was    found between years in healthcare and the TST as well as the QFT.</p>        <p>Due to colliniarity    problems age and years working in healthcare could not be introduced in the    same model. Therefore, the effect of these two variables on TST or QFT could    not be distinguished.</p>     <p>Most often TST+/QFT– results (47.1%) followed by concordant positive results (31.2%) occurred (Table V). With age the number of concordant positive results increased while the proportion of TST+/QFT– discordant results decreased. Repeated BCG vaccination increased the number of TST+/QFT– discordance. The smaller the interval after BCG vaccination the higher was the proportion of TST+/QFT– discordance. Nurses had less often positive concordant results than administratives, auxiliaries and physicians. At the same time, they had the highest rate of TST+/QFT–discordance. Surprisingly, the higher the assumed risk of infection the lower was the proportion of TST+/QFT+ concordance. Years working in healthcare increased the probability of TST+/QFT+ concordance but were not associated with TST+/QFT– discordance.</p>      <p>&nbsp;</p>     <p><b>Table V</b> – Concordant and discordant tuberculin skin test (TST) >10 mm and interferon-ã-release assay  (IGRA) results depending on putative risk factors</p> <img src="/img/revistas/pne/v16n2/16n2a02t5.gif">      
<p>&nbsp;</p>      <p>In these 1682 HCWs for whom TST and QFT results are available, active TB was dia gnosed in 9 HCWs. Diagnosis was based on culture confirmed positive smear in 7 cases, on culture in 1 and on PCR also in 1.</p>      ]]></body>
<body><![CDATA[<p>At the time of diagnosis TST and QFT were positive in all active TB cases. The study period covers 24 month, therefore the average annual incidence rate was 268/100 000.</p>      <p>&nbsp;</p>      <p><b>Discussion</b></p>      <p>The study presented here is one of the largest European studies analyzing risk    factors for LTBI by using QFT and TST simultaneously. It is also the only cross–sectional    study that observed active TB in HCWs in a cross-sectional design. The agreement    between TST and QFT was low and could not be improved by increasing the cut    off for the TST from &gt;10 to &gt;15 mm because this increased the proportion    of TST -/QFT+ results in the whole population from 2% to 12%. TST was more than    twice as often positive than the QFT. Therefore, TST+/ QFT– results were more    often observed than concordant negative or positive results.</p>        <p>In none of the    HCWs with a TST+/QFT– result active TB was diagnosed during the study period.</p>        <p>So far little is known about the effect of repeated BCG vaccination on the probability    of TST+/IGRA– discordant results<sup><a href="#20">20</a><a name="top20"></a>,<a href="#21">21</a><a name="top21"></a></sup>.    According to the Portuguese National Vaccination Plan, BCG vaccination is administered    in newborns<sup><a href="#18">18</a><a name="top18"></a></sup>. Therefore, the    effect of BCG vaccination on TST and QFT could not be studied. Nevertheless    it could be shown that repeated BCG vaccination increased the probability of    TST+/QFT– results. When re -vaccination was performed during the last 10 years    the chance for discordant TST+/ QFT– results was highest (69%) while at the    same time probability of concordant positive results was low (15.2%).</p>        <p>Contrary    to our preliminary analysis with a smaller sample not only QFT but also TST    showed that years working in healthcare are a risk factor for LTBI<sup><a href="#22">22</a><a name="top22"></a></sup>.    Surprisingly, neither risk assessment nor profession was associated with TST    or IGRA. In the two European fingerprint studies, the majority of workrelated    active TB cases occurred when the infection risk was not suspected and preventive    measures were not taken<sup><a href="#23">23</a><a name="top23"></a>,<a href="#24">24</a><a name="top24"></a></sup>.    Rotation of the staff is another explanation for the lack of this association,    as well as the crosssectional design of our study, which might dilute the expected    association.</p>        <p>The high proportion of TST positive HCWs with repeated BCG vaccination    corroborates the conclusion of other authors that TST is not very helpful in    populations in which most people are vaccinated and in which vaccination is    repeated<sup><a href="#25">25</a></sup><a name="top25"></a>. In those populations    the QFT is a promising alternative even though it is still not clear how the    QFT will perform in serial testing.</p>        <p>While unlike with the TST<sup><a href="#26">26</a><a name="top26"></a></sup>,    the test results cannot be influence by previous QFT, the definition for conversions    and reversions of the QFT are not yet well established. Further research will    have to elucidate the question about how changes in interferon-ã concentration    over time indicate real new infections or clearance of the Mycobacteria can    be distinguished from changes in concentration due to natural    variation<sup><a href="#27">27</a><a name="top27"></a>,<a href="#28">28</a><a name="top28"></a></sup>.</p>        <p>Additionally, and despite our increasing knowledge, several key questions about    latent infection and reactivation of <i>M. tuberculosis </i>remain unanswered.    Particularly, it should be noted that both the TST and the IGRA are designed    to identify an adaptive immune response against <i>M. tuberculosis</i>, but    not necessarily a latent infection. A positive result of currently available    diagnostic tests is primarily a measure of an immunological response to stimulation    by mycobacterial antigens that should not, therefore, be equated with the presence    of live <i>M. tuberculosis </i>in the human host. The proportion of individuals    who truly remain infected with <i>M. tuberculosis </i>after TST or IGRA conversion    is unknown. It is also uncertain how long adaptive immune responses towards    mycobacterial antigens persist in the absence of live mycobacteria. For these    reasons, according to the recently published TBNET consensus statement regarding    latent TB, based on the informative value presently derived by IGRA and TST,    the term “latent infection” would at best implicate “lasting tuberculosis immune    responses” and not necessarily identify a true latent  infection with viable    microorganisms and potential risk of developing active disease<sup><a href="#29">29</a><a name="top29"></a>,<a href="#30">30</a><a name="top30"></a></sup>.    Further studies are needed. Portuguese LTBI treatment guidelines<sup><a href="#31">31</a><a name="top31"></a></sup>,    which were revised in 2006, need to be updated, in order to address this question.    Whether treatment can be monitored by follow-up of the interferon-ã release    is another interesting question to be studied in future<sup><a href="#32">32</a><a name="top32"></a></sup>.</p>        ]]></body>
<body><![CDATA[<p>Considering the limitations that both tests present, the best solution seems    to be the use of both, using the IGRA higher specificity for confirming a positive    TST. This option allows us to take advantage of the best characteristics of    each test<sup><a href="#30">30</a><a name="top30"></a></sup>.</p>      <p>&nbsp;</p>      <p><b>Bibliography</b></p>      <!-- ref --><p><a href="#top1">1</a><a name="1"></a>. Saleiro S, Santos AR, Vidal O, Carvalho    T, Torres Costa J, Marques JA. Tuberculosis in hospital  department health care    workers. Rev Port Pneumol 2007; 13(6):789-799.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000086&pid=S0873-2159201000020000200001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a href="#top1">2</a><a name="1"></a>. Seidler A, Nienhaus A, Diel R. Review    of epidemiological studies on the occupational risk of tuberculosis in low-incidence    areas. Respiration 2005; 72(4):431-446.</p>      <p><a href="#top1">3</a><a name="1"></a>. Menzies D, Joshi R, Pai M. Risk of tuberculosis    infection and disease associated with work in health care settings. Int J Tuberc    Lung Dis 2007; 11(6):593-605.</p>      <p><a href="#top4">4</a><a name="4"></a>. CDC – Center for Disease Control and    Prevention. Guidelines for Preventing the Transmission of <i>Mycobacterium tuberculosis    </i>in Healthcare Settings, 2005. MMWR 2005; 54(RR-17):1-141.</p>      <p><a href="#top5">5</a><a name="5"></a>. Menzies D. What does tuberculin reactivity    after Bacille Calmette-Guerin vaccination tell us? Clin infect Dis 2000; 31(Suppl    3):S71-S74.</p>      <p><a href="#top6">6</a><a name="6"></a>. Andersen P, Munk ME, Pollock JM, Doherty    TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356(9235):1099-1104.</p>      <p><a href="#top7">7</a><a name="7"></a>. Nahid P, Pai M, Hopewell PC. Advances    in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 2006; 3:103-110.</p>      ]]></body>
<body><![CDATA[<p><a href="#top8">8</a><a name="8"></a>. Pai M, Riley LW, Colford JM. Interferon-gamma    assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect    Dis 2004; 4:761-776.</p>      <p><a href="#top9">9</a><a name="9"></a>. Menzies D, Pai M, Comstock G. Meta-analysis:    New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty    and recommendations for research. Ann Intern Med 2007; 146:340-352.</p>      <p><a href="#top10">10</a><a name="10"></a>. Diel R, Loddenkemper R, Meywald -Walter    K, Niemann S, Nienhaus A: Predictive value of a whole blood IFN -{gamma} assay    for the development of active TB disease. Am J Respir Crit Care Med 2008; 177:1164-1170.</p>      <p><a href="#top11">11</a><a name="11"></a>. Harada N, Nakajima Y, Higuchi K,    Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood    interferon-ã and Mantoux testing among Japanese healthcare workers. Infection    Control and Hospital Epidemiology 2006; 27(5):442-448.</p>      <p><a href="#top11">12</a><a name="11"></a>. Soberg B, Andersen AB, Larsen HK,    Weldingh K, Andersen P, Kofoerd K, Ravn P. Detecting a low prevalence of latent    tuberculosis among health care workers in Denmark detected by M. tuberculosis    specific INF-ã whole-blood test. Scandinavian Journal of Infectious Diseases    2007; 39:554-559.</p>      <p><a href="#top11">13</a><a name="11"></a>. Kobashi Y, Obase Y, Fukuda M, Yoshida    K, Miyashita N, Fujii M, Oka M. Usefulness of QuantiFERON TB-2G, a diagnostic    method for latent tuberculosis infection, in a contact investigation of health    care workers. Intern Med 2007; 46(18):1543-1549.</p>      <p><a href="#top11">14</a><a name="11"></a>. Mirtskhulava V, Kempker R, Shields    KL, Leonard MK, Tsertsvadze T, del Rio C, Salakaia A, Blumberg HM. Prevalence    and risk factors for latent tuberculosis infection among health care workers    in Georgia. Int J Tuberc Lung Dis 2008; 12(5):513-519.</p>      <p><a href="#top11">15</a><a name="11"></a>. Nienhaus A, Schablon A, Siano B,    le Bacle C, Diel R. Evaluation of the interferon-gamma release assay in healthcare    workers. Int Arch Occup Environ Health 2008; 81:295-300.</p>      <p><a href="#top11">16</a><a name="11"></a>. Schablon A, Beckmann G, Harling M,    Diel R, Nienhaus A. Prevalence of latent tuberculosis infection among healthcare    workers in a hospital for pulmonary diseases. J Occup Med Toxicol 2009; 4:1.</p>      <p><a href="#top11">17</a><a name="11"></a>. Vinton P, Mihrshahi S, Johnson P;    Jenkin GA; Jolley D, Biggs BA. Comparison of QuantiFERON-TB gold in-tube test    and tuberculin skin test for identification of latent <i>Mycobacterium tuberculosis    </i>infection in healthcare staff and association between positive test results    and known risk factors for infection. Infection Control and Hospital Epidemiology    2009; 30(3), online first.</p>      ]]></body>
<body><![CDATA[<p><a href="#top18">18</a><a name="18"></a>. Programa Nacional de Vacinação. Direcção-Geral    de Saúde – Ministério da Saúde. Available at <a href="http://www.dgsaude.pt/upload/membro.id/ficheiros/i007442.pdf" target="_blank">http://www.dgsaude.pt/upload/membro.id/ficheiros/i007442.pdf</a>    (accessed May 1st, 2009)</p>      <p><a href="#top19">19</a><a name="19"></a>. Hosmer D, Lemeshow S. Applied logistic    regression. New York, NY: John Wiley &amp; Sons 2000.</p>      <p><a href="#top20">20</a><a name="20"></a>. Farhat M, Greenaway, Pai M, Menzies    D. Falsepositive tuberculin skin tests: what is the absolute effect of BCG and    non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10(11):1192-1204.</p>      <p><a href="#top21">21</a><a name="21"></a>. Nienhaus A, Schablon A, Diel R. Interferon    -ã release assay for the diagnosis of latent TB infection–analysis of discordant    results, when compared to the tuberculin skin test. PLoS ONE 2008; 3(7):e2665.</p>      <p><a href="#top22">22</a><a name="22"></a>. Torres Costa Torres Costa J, Sá R,    Cardoso MJ, Silva R, Ferreira J, Ribeiro C, Miranda M, Plácido JL, Nienhaus    A. Tuberculosis screening in Portuguese healthcare workers using the tuberculin    skin test and the interferon-ã release assay. Eur Resp J 2009 (in press).</p>      <p><a href="#top23">23</a><a name="23"></a>. Diel R, Seidler A, Nienhaus A, Rusch-Gerdes    S, Niemann S. Occupational risk of tuberculosis transmission in a low incidence    area. Respir Res 2005; 6(1):35-45.</p>      <p><a href="#top24">24</a><a name="24"></a>. De Vries G, Sebek MM, Lambregts-van    Weezenbeek CS. Health-care workers with tuberculosis infected during work. Eur    Respir J 2006; 28(6): 1216-21</p>       <p><a href="#top25">25</a><a name="25"></a>. Lee S S-J, Liu Y-C, Huang T-S, Chen    Y-S, Tsai H-C,Wann S-R, Lin H-H. Comparison of the interferon-ã release assay    and the tuberculin skin test for contact investigation of tuberculosis in BCG-vaccinated    health care workers. Scandinavian Journal of Infectious Disease 2008; 40(5):    373-380.</p>      <p><a href="#top26">26</a><a name="26"></a>. Menzies D. Interpretation of repeated    tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care    Med 1999; 159:15-21. </p>      <p><a href="#top27">27</a><a name="27"></a>. Pai M, Joshi R, Dogra S, Zwerling    AA, Gajalakshmi D, Goswami K, Reddy MVR, Kalantri S, Hill PC, Menzies D, Hopewell    PC. T-cell assay conversions and reversions among household contacts of tuberculosis    patients in rural India Int J Tuberc Lung Dis 2009; 13(1):84-92.</p>      ]]></body>
<body><![CDATA[<p><a href="#top28">28</a><a name="28"></a>. Yoshiyama T, Harada N, Higuchi K,    Nakajima Y, Ogata H. Estimation of incidence of tuberculosis infection in healthcare    workers using repeated interferon-ã assays. Epidemiol Infect 2009 (ahead of    print).</p>      <p><a href="#top29">29</a><a name="29"></a>. Mack U, Migliori GB, Sester M, Rieder    HL, Ehlers S, Goletti D, <i>et al</i>, for the TBNET. LTBI: latent tuberculosis    infection or lasting immune responses to <i>M. tuberculosis? </i>– A TBNET consensus    statement. Eur Respir J 2009; 33: 956-973.</p>      <!-- ref --><p><a href="#top30">30</a><a name="30"></a>. Duarte R. Teste tuberculínico. Como    optimizar? Rev Port Pneumol 2009; 15 (2):295-304.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000115&pid=S0873-2159201000020000200002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a href="#top31">31</a><a name="31"></a>. Duarte R, Amado J, Lucas H, Sapage    JM, Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia.    Tratamento da tuberculose latente: Revisão das normas, 2006. Rev Port Pneumol    2007; 13(3): 397-418&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000116&pid=S0873-2159201000020000200003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a href="#top32">32</a><a name="32"></a>. Pai M, Joshi R, Dogra S, Mendiratta    DK, Narang P, Dheda K Kalantri S. Persistently elevated T cell interferon -ã    response after treatment for latent tuberculosis infection among healthcare    workers in India: a preliminary report. Journal of Occupational Medicine and    Toxicology 2006; 1:7.</p>      <p>&nbsp;</p>      <p><b><a name="c1"></a><a href="#topc1">Correspondência/</a></b><b><i>Correspondence to:</i></b></p>     <p>José Castela Torres Costa</p>     <p>Estrada de St.ª Luzia 269</p>     <p>4900-408 Viana do Castelo</p>     ]]></body>
<body><![CDATA[<p><i>e-mail: </i><a href="mailto:zecatoco@sapo.pt">zecatoco@sapo.pt</a></p>      <p>&nbsp;</p>      <p>Recebido para publicação/<i>received for publication:</i>09.06.05</p>     <p>Aceite para publicação/<i>accepted for publication:</i>09.07.23</p>       ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saleiro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tuberculosis in hospital department health care workers]]></article-title>
<source><![CDATA[Rev Port Pneumol]]></source>
<year>2007</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>789-799</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Teste tuberculínico. Como optimizar?]]></article-title>
<source><![CDATA[Rev Port Pneumol]]></source>
<year>2009</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>295-304</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sapage]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia. Tratamento da tuberculose latente: Revisão das normas, 2006.]]></article-title>
<source><![CDATA[Rev Port Pneumol]]></source>
<year>2007</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>397-418</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
